Inovio Pharmaceuticals (INO) Non-Current Assets (2010 - 2026)

Inovio Pharmaceuticals has disclosed Non-Current Assets across 17 years of filings, most recently posting $9.5 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 39.03% year-over-year to $9.5 million; the TTM figure through Jun 2026 stood at $47.2 million (down 23.94% YoY), while the FY2025 annual figure was $13.2 million, down 14.19% from the prior year.
• Non-Current Assets came in at $9.5 million for Q2 2026 at Inovio Pharmaceuticals, down from $10.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $45.6 million in Q1 2022 to a low of $9.5 million in Q2 2026.
• Average Non-Current Assets over 5 years is $22.5 million, with a median of $16.8 million recorded in 2024.
• Year-over-year, Non-Current Assets slumped 56.11% in 2023 and declined 4.27% in 2025.
• Over 5 years, Non-Current Assets stood at $33.3 million in 2022, then slumped by 46.42% to $17.8 million in 2023, then fell by 13.85% to $15.4 million in 2024, then dropped by 14.19% to $13.2 million in 2025, then retreated by 28.14% to $9.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $9.5 million in Q2 2026, $10.3 million in Q1 2026, and $13.2 million in Q4 2025.